Alcon, Sirion sales and marketing update

Alcon also will receive exclusive, worldwide rights, excluding Latin America, to develop and commercialize Zyclorin cyclosporine. The topical ophthalmic immunomodulator and immunosuppressive agent is in preclinical testing for ocular surface diseases, including dry eye. JPMorgan advised Sirion on the deal, which is expected to close this quarter. Financial terms were not disclosed. ...